IL309890A - Monovalent anti-properdin antibodies and antibody fragments - Google Patents
Monovalent anti-properdin antibodies and antibody fragmentsInfo
- Publication number
- IL309890A IL309890A IL309890A IL30989024A IL309890A IL 309890 A IL309890 A IL 309890A IL 309890 A IL309890 A IL 309890A IL 30989024 A IL30989024 A IL 30989024A IL 309890 A IL309890 A IL 309890A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- properdin
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452187P | 2017-01-30 | 2017-01-30 | |
| PCT/US2018/015985 WO2018140956A1 (en) | 2017-01-30 | 2018-01-30 | Monovalent anti-properdin antibodies and antibody fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309890A true IL309890A (en) | 2024-03-01 |
Family
ID=62978808
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309890A IL309890A (en) | 2017-01-30 | 2018-01-30 | Monovalent anti-properdin antibodies and antibody fragments |
| IL267898A IL267898B2 (en) | 2017-01-30 | 2018-01-30 | Monovalent antibodies against properdin and their fragments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267898A IL267898B2 (en) | 2017-01-30 | 2018-01-30 | Monovalent antibodies against properdin and their fragments |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11198725B2 (https=) |
| EP (1) | EP3573661A4 (https=) |
| JP (3) | JP7101684B2 (https=) |
| KR (2) | KR20230173731A (https=) |
| CN (2) | CN118184777A (https=) |
| AU (2) | AU2018212012B2 (https=) |
| BR (1) | BR112019014652A2 (https=) |
| CA (1) | CA3049806A1 (https=) |
| CO (1) | CO2019007686A2 (https=) |
| IL (2) | IL309890A (https=) |
| MX (3) | MX2019008827A (https=) |
| WO (1) | WO2018140956A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118184777A (zh) * | 2017-01-30 | 2024-06-14 | 亚力兄制药公司 | 单价抗备解素抗体及抗体片段 |
| BR112019028269A2 (pt) | 2017-07-11 | 2020-07-14 | Alexion Pharmaceuticals, Inc. | polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão |
| JP7222075B2 (ja) * | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
| CN115003694A (zh) * | 2020-01-08 | 2022-09-02 | 载度思生命科学有限公司 | 抗备解素抗体及其制备 |
| WO2022066774A1 (en) | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| CN114432449B (zh) * | 2020-10-30 | 2024-05-28 | 广州市妇女儿童医疗中心 | 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用 |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| TW202413435A (zh) * | 2022-08-05 | 2024-04-01 | 美商艾力克森製藥公司 | 融合蛋白的藥物組成物及其使用方法 |
| TW202417490A (zh) * | 2022-08-31 | 2024-05-01 | 美商艾力克森製藥公司 | 用於治療鐮狀細胞病的融合多肽之劑量及投與 |
| EP4395825A4 (en) * | 2022-11-25 | 2025-08-20 | Linno Pharmaceuticals Inc | PROPERDIN-BINDING PROTEIN AND ITS USE |
| CN120399074B (zh) * | 2023-06-02 | 2025-12-30 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| WO2006081249A2 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Conjugates of biologically active proteins having a modified in vivo half-life |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8435512B2 (en) * | 2008-03-03 | 2013-05-07 | Novelmed Therapeutics, Inc. | Anti-properdin antibodies |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| AU2011224224B2 (en) * | 2010-03-10 | 2015-07-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| EA202092589A3 (ru) | 2010-11-08 | 2021-06-30 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| JP6293659B2 (ja) | 2011-07-01 | 2018-03-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗プロペルジン抗体およびその使用 |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| PE20150159A1 (es) * | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
| CN104114187A (zh) * | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| EP2904014A4 (en) | 2012-10-04 | 2016-09-28 | Novelmed Therapeutics Inc | FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN118184777A (zh) * | 2017-01-30 | 2024-06-14 | 亚力兄制药公司 | 单价抗备解素抗体及抗体片段 |
| CN110003335B (zh) * | 2019-04-12 | 2023-07-04 | 深圳普瑞金生物药业股份有限公司 | Cd47单域抗体、核酸及试剂盒 |
-
2018
- 2018-01-30 CN CN202410325026.7A patent/CN118184777A/zh active Pending
- 2018-01-30 CA CA3049806A patent/CA3049806A1/en active Pending
- 2018-01-30 MX MX2019008827A patent/MX2019008827A/es unknown
- 2018-01-30 IL IL309890A patent/IL309890A/en unknown
- 2018-01-30 WO PCT/US2018/015985 patent/WO2018140956A1/en not_active Ceased
- 2018-01-30 EP EP18744926.9A patent/EP3573661A4/en active Pending
- 2018-01-30 AU AU2018212012A patent/AU2018212012B2/en active Active
- 2018-01-30 KR KR1020237042534A patent/KR20230173731A/ko not_active Ceased
- 2018-01-30 US US16/479,335 patent/US11198725B2/en active Active
- 2018-01-30 KR KR1020197021910A patent/KR102613874B1/ko active Active
- 2018-01-30 BR BR112019014652-0A patent/BR112019014652A2/pt active Search and Examination
- 2018-01-30 JP JP2019538396A patent/JP7101684B2/ja active Active
- 2018-01-30 IL IL267898A patent/IL267898B2/en unknown
- 2018-01-30 CN CN201880008892.6A patent/CN110831626B/zh active Active
-
2019
- 2019-07-17 CO CONC2019/0007686A patent/CO2019007686A2/es unknown
- 2019-07-25 MX MX2023004333A patent/MX2023004333A/es unknown
- 2019-07-25 MX MX2023007840A patent/MX2023007840A/es unknown
-
2021
- 2021-11-09 US US17/522,028 patent/US12497445B2/en active Active
-
2022
- 2022-07-04 JP JP2022107980A patent/JP2022153405A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095141A patent/JP2024116321A/ja active Pending
-
2025
- 2025-02-03 AU AU2025200709A patent/AU2025200709A1/en active Pending
- 2025-11-13 US US19/387,895 patent/US20260070963A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019007686A2 (es) | 2019-07-31 |
| IL267898A (en) | 2019-09-26 |
| JP2024116321A (ja) | 2024-08-27 |
| KR20230173731A (ko) | 2023-12-27 |
| CA3049806A1 (en) | 2018-08-02 |
| US11198725B2 (en) | 2021-12-14 |
| RU2019124873A (ru) | 2021-03-01 |
| RU2019124873A3 (https=) | 2021-03-01 |
| AU2018212012A1 (en) | 2019-07-25 |
| MX2023004333A (es) | 2023-05-04 |
| US20220162292A1 (en) | 2022-05-26 |
| US20260070963A1 (en) | 2026-03-12 |
| KR20190111946A (ko) | 2019-10-02 |
| MX2019008827A (es) | 2019-09-26 |
| US20190352381A1 (en) | 2019-11-21 |
| MX2023007840A (es) | 2023-07-07 |
| IL267898B2 (en) | 2024-06-01 |
| AU2018212012B2 (en) | 2025-02-13 |
| JP2020507561A (ja) | 2020-03-12 |
| CN118184777A (zh) | 2024-06-14 |
| JP2022153405A (ja) | 2022-10-12 |
| EP3573661A1 (en) | 2019-12-04 |
| WO2018140956A1 (en) | 2018-08-02 |
| CN110831626B (zh) | 2024-04-19 |
| EP3573661A4 (en) | 2020-08-12 |
| BR112019014652A2 (pt) | 2020-08-18 |
| US12497445B2 (en) | 2025-12-16 |
| AU2025200709A1 (en) | 2025-02-20 |
| KR102613874B1 (ko) | 2023-12-15 |
| JP7101684B2 (ja) | 2022-07-15 |
| IL267898B1 (en) | 2024-02-01 |
| CN110831626A (zh) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497445B2 (en) | Monovalent anti-properdin antibodies and antibody fragments | |
| US11286312B2 (en) | Multispecific antibodies | |
| US20250163138A1 (en) | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof | |
| RU2790103C2 (ru) | Моновалентные антитела к пропердину и фрагменты антител | |
| HK40112563A (zh) | 单价抗备解素抗体及抗体片段 | |
| HK40024594A (en) | Monovalent anti-properdin antibodies and antibody fragments | |
| HK40024594B (zh) | 单价抗备解素抗体及抗体片段 | |
| EP4396226A2 (en) | Monospecific and bispecific antibodies and antigen binding fragments thereof |